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X-Ray Structure of the hROR LBD at 1.63 A˚:
Structural and Functional Data that Cholesterol or a
Cholesterol Derivative Is the Natural Ligand of ROR
thymus and seems to be important for thymopoiesis
and lymphoid organogenesis [5].
The human ROR gene encodes at least four distinct
splicing isoforms, ROR1–3 and ROR4 (also termed
RZR), for which the DBD and LBD are conserved, but
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Biomolecules Production Unit A/T-rich sequences immediately preceding a site core
motif AGGTCA (RORE), although the different isoforms3 Arthritis and Bone Metabolism
Bone Metabolism Unit display different binding affinities for these response
elements [7]. Several target genes of RORbearing suchNovartis Pharma AG
CH-4002 Basel response elements have been identified including Apoli-
poprotein A-I, Apolipoprotein C-III, and PPAR [8–10].Switzerland
Positional cloning showed that staggerer mice, a
spontaneous mutant mice, were missing the ROR LBD
[11]. Conversely, ROR knockout mice have been gener-Summary
ated and were found to recapitulate the phenotype of
the staggerer mice [12]. Staggerer mice are character-The retinoic acid-related orphan receptor  (ROR)
ized by severe cerebella ataxia due to a developmentalis an orphan member of the subfamily 1 of nuclear
defect of Purkinje cells [13]. Recent in-depth studies ofhormone receptors. No X-ray structure of ROR has
the neurological staggerer mutant broadly expand thebeen described so far, and no ligand has been identi-
potential function of ROR beyond the nervous system.fied. We describe the first crystal structure of the li-
In particular, it has been shown that staggerer micegand binding domain (LBD) of ROR, at 1.63 A˚ resolu-
exhibit defects in the immune [14] and inflammatorytion. This structure revealed a ligand present in the
response [15]. They are prone to increased atheroscle-ligand binding pocket (LBP), which was identified by
rotic lesions and hypoliproteinemia when fed with a richX-ray crystallography as cholest-5-en-3-ol (choles-
lipid diet [16]. In addition, a role of ROR in bone metabo-terol). Moreover, ROR transcriptional activity could
lism has been postulated, since the staggerer mice dis-be modulated by changes in intracellular cholesterol
play an osteopenic phenotype [17] (for a review, see [18]).level or mutation of residues involved in cholesterol
Two putative ligands have been proposed for ROR,binding. These findings suggest that ROR could play
namely melatonin and thiazolidine diones, which werea key role in the regulation of cholesterol homeostasis
shown to increase transcriptional activity of ROR [19].and thus represents an important drug target in cho-
However, these data remain controversial, and ROR islesterol-related diseases.
still considered as an orphan nuclear receptor. Several
lines of evidence have contributed to the idea that ROR
Introduction displays a constitutive transcriptional activity. It has
been shown that ROR could efficiently recruit coactiva-
The group of retinoic acid-related orphan nuclear recep- tors, such as P300 [20] and GRIP1 [21]. This suggests
tors (ROR) is encoded by three different genes (, , that ROR is in a state where helix 12 (H12) of its LBD
and ) [1]. Like other members of the nuclear receptor is in a so-called agonist position, allowing the recruit-
family, ROR (NR1F1) [2] contains a DNA binding do- ment of coactivators [22]. So far, no X-ray structure for
main (DBD), regulating the expression of target genes ROR has been reported. In a recent study [23], a model
upon binding to cognate response elements, and a li- of the ROR LBD was proposed based on its homology
gand binding domain (LBD). The ROR LBD displays with the thyroid hormone receptor  (TR). They postu-
63% and 58% homology with those of ROR and ROR, lated that the ROR LBD could be found in an agonist
respectively, but only 24%–25% with the LBD of other conformation without a ligand bound, since in their
nuclear receptors such as T3R, VDR, and RAR. The model, large bulky hydrophobic residues partially fill the
distribution of ROR mRNA suggests that this receptor ligand binding pocket (LBP) and therefore mimic the
is widely expressed and functions in several organs in- presence of a ligand. This would enable the ligand-inde-
cluding brain, heart, liver, testis, and skin [3]. In contrast, pendent recruitment of coactivators, similar to the re-
expression of ROR is restricted to areas of the central cently determined X-ray structure of ERR [24]. The
nervous system implicated in the processing of sensory structure of ROR LBD expressed in Escherichia coli
information such as the pineal gland, retina, and supra- was recently solved with a fortuitous ligand identified
chiasmatic nuclei. This suggests a role for ROR in the as stearic acid [25]. However, stearic acid was consid-
control of the circadian rhythm, as evidenced by studies ered to be a pseudoligand, since it did not trigger any
on knockout mice [4]. ROR is highly expressed in the additional transcriptional activity of ROR, only partially
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Table 1. ROR LBD Structure Determination
Data set Native 1 Native 2 MeHgAc
Reflections
Measured (N) 109,306 141,730 121,716
Unique (N) 26,882 38,783 25,136
Rsyma (%) 5.6 4.0 5.7
Resolution (A˚) 15.0–1.88 15.0–1.63 10.0–1.88
Completeness (%) 99.2 95.36 93.6
Phasing powerb 1.16
Rscalec (%) 23.8
Number of sites 4
Refinement
Space group P21
Cell a  54.8 A˚, b  49.7 A˚,
c  60.5 A˚,   98.4
Resolution (A˚) 15.0–1.63
Reflections in working set; in test set 36,570; 1,907
Rcrystd (%) 19.9
Rfree (%) 23.0
Rmsd bond lengths (A˚) 0.009
Rmsd bond angles () 1.11
Average B factor for nonhydrogen
atoms (A˚2); number of atoms
Protein 26.6; 2,067
Ligand 16.7; 28
Water molecules 42.2; 419
a Rsym  |Iavg  II|/II
b Phasing power  |FH|/||FPH obs|  |FPH calc|| (calculated for acentric data)
c Rscale  |FPH  FP|/FP
d Rcryst  |FP  FPcalc|/FP, where FP and FPcalc are observed and calculated structure factors, Rfree is calculated for a randomly chosen 5% of
reflections, and Rcryst is calculated for the remaining 95% of reflections.
MeHgAc, a methylmercuric acetate heavy atom derivative data set; native 1 is the native data set used for SIRAS structure determination
and initial refinement steps; native 2 is the native data set used for final refinement; rmsd, root-mean-square deviation from ideal geometry.
filled the ROR LBP, and adopted multiple low-energy sulting in a high titer of soluble protein that was purified
to homogeneity by three-step chromatography. The pro-conformations.
Here, we present the first crystal structure of the ROR tein remained stable during both purification and crys-
tallization without addition of external ligands. Crystalli-LBD. In addition, a ligand was found unexpectedly to
be present in the LBP and was identified by X-ray crys- zation trials in the presence of a coactivator peptide
(GRIP-1, residues 686–700) did not yield suitable crys-tallography as cholest-5-en-3-ol (cholesterol). The
presence of cholesterol as a ligand was confirmed inde- tals. Likewise, untagged protein obtained through His
tag removal with the PreScission protease failed to crys-pendently by ESI-MS and GC-MS analysis. Using ESI-
MS, we also show that cholesterol bound to ROR can tallize. Well-diffracting crystals were only obtained with
the uncleaved His-tagged protein having the intact Pre-be exchanged with cholesterol sulfate. This shows that
cholesterol is not simply a structural cofactor. We also Scission site. The structure could not be solved by mo-
lecular replacement using models based on hRAR LBDpresent experimental evidence that supports a physio-
logical role of cholesterol or of a cholesterol derivative or hTR LBD. Indeed, the coordinates of ROR LBD
became available only when our structure was fully re-in the regulation of the transcriptional activity of ROR.
We speculate that ROR belongs to the new group of fined. Therefore, the single isomorphous replacement
with anomalous scattering method (SIRAS) based on aorphan nuclear receptors involved in lipid metabolism
that might act as lipid sensors, as recently shown for liver methylmercuric acetate heavy atom data set was used
(Table 1 and Experimental Procedures). The final RcrystX-activated receptor (LXR) and Farnesoid X-activated
receptor (FXR) [26, 27]. and Rfree were 19.9% and 23.0%, respectively, using
data in the resolution range of 15 A˚–1.63 A˚ (Table 1).
PROCHECK analysis [28] showed that there were noResults
outliers in the Ramachandran plot. The geometry was
excellent and the overall G factor was 0.39.Structure Determination of the ROR LBD
Initially, human ROR LBD (residues 271–523 with a
cleavable N-terminal His tag, numbered according to Overall Structure of the ROR LBD
The results of the crystallographic refinement are sum-splice variant 1 of SWISS-PROT entry P35398) was ex-
pressed in Escherichia coli, but yielded only insoluble marized in Table 1. The last two amino acids of the
N-terminal His tag, all amino acids of the PreScissionprotein accumulating in inclusion bodies, which could
not be refolded properly. Therefore, ROR LBD was cleavage site, and amino acids 271–511 of human ROR
LBD were modeled into the electron density map andproduced in the Baculovirus expression system, re-
Crystal Structure and Ligand of ROR
1699
Figure 1. Crystal Structure of the Complex
between Human ROR LBD and Cholesterol
(A) Sequence of the construct used in crystal-
lization. It consists of the His tag (blue), Pre-
Scission site (green), and residues 271–523
from ROR (black). Residue numbering is
based on splice variant 1 of SWISS-PROT
entry P35398. The secondary structure ele-
ments are shown below the sequence. The
underlined amino acids are present in the fi-
nal refined coordinates. Amino acids that
have a nonhydrogen atom closer than 4 A˚ to
cholesterol are highlighted in red.
(B) The binding of the N-terminal His tag and
PreScission site to the LXXLL binding site
(AF-2 site) of a neighboring molecule in the
crystal lattice. The tag is colored as follows:
white, carbon; blue, nitrogen; red, oxygen.
The ribbon backbone of ROR is in red and
its amino acids are colored as the tag, except
for carbon being yellow. Residues K339(H3)
and E509(H12) form the “charged clamp,”
and their hydrogen bonds to the main chain
of the tag are indicated as dotted lines.
(C) Ribbon drawing showing the ternary com-
plex of ROR LBD, cholesterol, and the
N-terminal tag from a neighboring molecule.
The N-terminal tag (from a neighboring mole-
cule) binding to the AF-2 site is shown as a
stick diagram (coloring as in [B]). It corre-
sponds to helix HP of the molecule shown as
a ribbon drawing. Cholesterol is shown as a
CPK model (carbon, yellow; oxygen, red), and the ligand binding pocket as a transparent surface (white). The putative entrance site to the
LBP is between H2 and H3.
(D) Same as in (C), but with the view turned by 90 around the vertical axis.
crystallographically refined (Figure 1A). The nomencla- size exclusion chromatography (data not shown). This
is consistent with the structural finding that there is ature of the secondary structure elements (Figure 1) is
based on the RXR LBD crystal structure [29] and is kink at C505-K506 in the dimerization helix H10, similar
to the kink at A411-K412 for ROR LBD [25]. The overallsimilar to the one used for ROR LBD [25]. PROCHECK
analysis shows for ROR LBD the following principal structures of ROR LBD and ROR LBD [25] are similar.
The root-mean-square deviation (rmsd) using the LSQsecondary structure elements (Figure 1A): H1(A271–
E286), H2(R292–Q297), H2*(Q305–N313), H3(R316– option from the program O [32 ] was 0.96 A˚ for 237 Cs
(using the corresponding amino acids 271–460, 465–511K339), H4(Q349–A358), H5(G359–R367), s0(F372–D373),
s1(T378–F381), s2(K384–A386), H6(P388–L394; 3/10 he- from ROR and 210–399, 404–450 from ROR). Dis-
tances of more than 2 A˚ between corresponding Cslix), H7(E397–C411), H8(E417–L428), H9(K439–N460),
H10(I466–R483), H11(H484–I494), H11*(P496–H502), after superposition are found for amino acids in H1, H2,
L3-4, and H4.and H12(P505–L510). Most ROR amino acids had well-
defined electron density, except for amino acids 461–
464 in loop L9-10, which had the highest B factors. The Ligand Binding Pocket and the Identification
of the Ligand as Cholesterol:The ROR LBD (Figure 1) adopts the canonical fold
for the NR-LBDs [30], but has a small three-stranded  The Deorphanization of ROR
Cholesterol could be identified unambiguously to besheet (amino acids 372-373, 378–381, and 384–386), and
in addition has the two helices H2* and H11* (amino the ligand present in the ROR-LBP due to the high-
resolution electron density maps (Figures 2A and 2B).acids 305–313 and 496–502), similar to ROR LBD [25].
An additional H2* helix is also found between H2 and This unexpected finding was supported independently
by mass spectrometry (see below), and demonstratesH3 for the peroxisome proliferator-activated receptors
[31]. H11* is unique to ROR LBD and ROR LBD [25] that ROR LBD expressed in Sf-9 insect cells is not in
an unliganded form, but bound to cholesterol.among the known LBD structures. ROR LBD is in an
agonist-bound state, as judged by the position of H12 The LBP of ROR is a large cavity that extends from
H12 to the loop L1-2 (Figures 1C and 1D). This is in con-[22]. H12 in this position, together with the H3-H4 region,
forms the interaction surface (AF-2) for the coactivator trast to the model proposed recently [23] where the LBP
of RORwas thought to be almost completely filled with[22]. In the crystal, there is one ROR LBD molecule in
the asymmetric unit (space group P21), which conse- hydrophobic side chains. The putative entry site for this
cavity lies between L1-2, H3, and the  sheet. It is thusquently cannot form a homodimer related by a 2-fold
axis with a neighboring molecule. Indeed, ROR LBD not near H12 as proposed for most other nuclear recep-
tor LBDs [22], but at a similar location for the entry sitewas shown to run as a monomer on native gels and by
Structure
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Figure 2. Detailed View of the LBP of Human ROR LBD and Its Interactions with Cholesterol
(A) Top: chemical formula of cholesterol with atom numbering. Bottom: two orthogonal views of unbiased 2Fo  Fc electron density map for
the ligand (contour level 1.0 , 1.88 A˚ resolution) at an initial stage of refinement, before cholesterol was included in the model. Superposed
is the final model of cholesterol (carbon, blue; oxygen, red).
(B) Final 2Fo  Fc electron density map in the LBP (contour level 1.0 , 1.63 A˚ resolution) and the final model (ROR: carbon, yellow; oxygen,
red; nitrogen, blue; sulfur, green; cholesterol: carbon, cyan; oxygen, red. Water molecules: oxygen, green). Selected water-mediated hydrogen
bonds in the hydrophilic part of the LBP are indicated as dashed lines.
(C) The probe-occupied surface of the LBP is depicted as a white transparent surface with residues of ROR lining it as stick models.
Cholesterol and water molecules are shown as CPK models (carbon, yellow; oxygen, red; water molecules, magenta). The hydrogen bond
between NE2-H484 and OH-Y507 (distance 2.7 A˚) is indicated as a dashed line. The chemical formula of cholesterol in the lower part is in a
similar orientation as the CPK model.
(D) Same as (C), but with the view turned by 180 around the vertical axis. This orientation is similar to the one in (B).
as has been hypothesized for PPAR- [31]. The surface The H3 side of the LBP, into which the 3-hydroxy
group of cholesterol points, is more polar and is formedaround the putative entry site comprises Y290(L1-2),
Y333(H3), Y380(s1), and the hydrophilic side chain amino by side chains from L1–2, H3, and H5. There are 13 well-
ordered water molecules in the hydrophilic part (Figuresacids Q289(L1-2), K326(H3), and E329(H3).
The AF-2 side of the LBP is formed by side chains 2B–2D). Five of these water molecules are among the
15 water molecules (from a total of 419 water molecules)from H5, H6, H7, H10, and H12 and is mainly hydropho-
bic, with the exception of H484(H11) and Y507(H12). that have the lowest B factors (16 A˚2–23 A˚2). The
3-hydroxy group of cholesterol makes, via a network ofThese latter side chains (conserved among the ROR
isotypes) form a hydrogen bond between NE2-H484 and well-ordered water molecules, water-mediated hydro-
gen bonds to OE1-Q289, N-Q289, N-Y290, O-A330,OH-Y507 (distance 2.7 A˚), which probably contributes
to the stabilization of H12 in the agonist position. The O-R367, NH1-R367, NH1-R370, N-D382, and N-G383.
The side chains of R367 and R370 on H5 contributeimportance of the latter hydrogen bond was confirmed
by the mutation experiment Y507F that led to ca. 2-fold to the generation of a positive electrostatic potential.
Cholesterol derivatives carrying a negatively chargedloss of ROR transcriptional activity (see below). C26
of the terminal isopropyl group of cholesterol (Figure substituent on the 3-hydroxy group (e.g., cholesterol
sulfate) may therefore have the potential for increased2A) makes van der Waals contacts with the side chain
of W320(H3), while C27 makes van der Waals contacts affinity.
The average B value for the ligand (16.7 A˚2) is lowerwith the side chain of I327(H3).
Crystal Structure and Ligand of ROR
1701
Figure 3. Exchange of Cholesterol with Cholesterol Sulfate Detected by Mass Spectrometry
Cholesterol sulfate was dissolved at 50 mM in DMSO and added at 2.5 mM final concentration to the (His)6ROR LBD270–523 solution at 135
	M. The resulting solution was incubated overnight at 37C. A control experiment was done by incubating the same amount of ROR LBD
protein with 5% DMSO under identical conditions. MaxEnt deconvoluted mass spectrum of (His)6ROR-LBD270–523 (top) and (His)6ROR LBD270–523
with cholesterol sulfate (bottom). The protein concentration was approximately 15 	M in 50 mM AcONH4 (pH 7.0). The spectra were recorded
under identical conditions with Vc  20 volts.
than the average B value for the protein (26.6 A˚2), consis- with OH-Y507 or NE2-H484, but not with a favorable
geometry. A bulky 27-OR group would only fit if Y507,tent with the fact that excellent electron density for all
nonhydrogen atoms of cholesterol is visible. Cholesterol and thus H12, moves away, thus possibly leading to an
antagonistic derivative. In summary, docking indicatesthus adopts a single, well-defined position in the LBP.
This is in contrast to the multiple low-energy conforma- that the above-mentioned hydroxysterols probably have
reduced affinity, while cholesterol sulfate should havetions described for the pseudoligand stearic acid pres-
ent in ROR LBD [25]. For cholesterol, there is a good increased affinity. Epicholesterol, cholestanol, and 7-
dehydro-cholesterol could fit in the LBP, if there is afit to the van der Waals surface of the hydrophobic part
of the LBP. In the hydrophilic part of the LBP, derivatives rearrangement of the water molecules in the LBP. The
derivative 5-cholesten-24-ethyl-3-ol-acetate wouldof cholesterol could be accepted, if water molecules are
displaced. The following amino acids have a nonhydro- lead to severe steric clashes with the LBP, and was thus
proposed as a negative control for the biological assays.gen atom closer than 4 A˚ to the ligand cholesterol:
W320(H3), C323(H3), K326(H3), I327(H3), A330(H3), The volume of the LBP for ROR is 722 A˚3 and thus
similar to the value of 766 A˚3 reported for ROR [25].V364(H5), R367(H5), M368(loop H5-s0), V379(s1),
Y380(s1), F381(s1), F391(H6), L394(H6), F399(H7), This is in contrast to the modeling result based on ROR,
which predicted a much smaller volume of 568 A˚3 forV403(H7), and H484(H11). The van der Waals volume of
cholesterol is 390 A˚3, thus lying slightly below the vol- ROR [25], and even more in contrast with another mod-
eling prediction giving a volume of 236 A˚3 [23]. A super-umes of 22(R)-hydroxycholesterol (405 A˚3 ) and 25-
hydroxycholesterol (407 A˚3 ), which are the natural li- position with the LBP of ROR shows that cholesterol
could also fit to ROR, if the side chains of Q265 andgands of LXR and SF-1, respectively [33]. In the X-ray
structure of ROR LBD, a 22(R)-hydroxy group would L388 change their conformations. This suggests that
the natural ligands of ROR and ROR could be similar.lead to a steric clash with CD1-I400 (2.7 A˚), while a 25-
hydroxy group would lead to close contact with CD2-
H484 (3.1 A˚) and CE2-F399 (3.2 A˚). A 25-hydroxy group The Coactivator Binding Site: The PreScission Site
Is a Mimic of a Coactivator Peptidecould fit, if the side chain of H484 changes its 
2 value
by 180. This would enable a hydrogen bond between No addition of coactivator peptides was necessary to
obtain well-diffracting crystals of ROR LBD. Surpris-the 25-hydroxy group and ND1-H484, at the cost of
losing the hydrogen bond between NE2-H484 and OH- ingly, the PreScission cleavage site (LEVLFQGP) flank-
ing the N-terminal His tag acted as a mimic of the LXXLLY507. This would probably destabilize H12 in the agonist
position and be energetically less favorable. A 27-hy- coactivator sequence. It adopts an -helical conforma-
tion (Figure 1, HP) and interacts with the coactivatordroxy group on cholesterol could make hydrogen bonds
Structure
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Figure 4. Transcriptional Activity of ROR
Wild-Type and Mutants
(A) Transcriptional activity of ROR wild-type
and mutants. U-20S were seeded at a density
of 1  105 cells/cm2 in 12-well plates and
transiently transfected with 0.50 	g expres-
sion vector for ROR or ROR mutants to-
gether with 1.0 	g ROREtkluc as indicated in
Experimental Procedures. Twenty-four hours
after transfection, cells were collected with
250 	l passive lysis buffer and luciferase ac-
tivity was determined in duplicate on 20	l cell
extracts. Luminescence data were corrected
with protein content and expressed as rela-
tive luminescence unit/	g protein (RLU). Re-
sults are expressed as % of induction com-
pared to the activity of wild-type ROR.
(B) Western blot analysis of extracts from
cells transfected as described in (A) with wild-
type and mutants. Whole-cell extracts were
prepared and Western blots were performed
as described in [17].
binding site of a neighboring molecule in the crystal of cholesterol as the major ligand (F.B. et al., unpub-
lished data).lattice (Figure 1). The backbone and side chain positions
of HP and the “charge clamp” capping interactions me-
diated by K339(H3) and E509(H12) with the peptide Cholesterol Bound to ROR Can Be Exchanged
backbone (Figure 1B) are very similar to the ones ob- In order to determine whether cholesterol is an obliga-
served for coactivator peptide complexes [24, 25, 31]. tory structural cofactor or can be exchanged, we tested
Helices HP of the PreScission cleavage site and H1 of by ESI-MS the ability of excess cholesterol sulfate (pre-
ROR LBD form a kink of ca.110 (Figures 1C and 1D), dicted by the X-ray structure to have higher affinity than
thus enabling the interaction of HP with the AF-2 site cholesterol) to displace cholesterol bound to ROR
of a neighboring molecule. We suggest that increasing LBD. Figure 3 shows the ESI-MS of ROR LBD prior to
crystal contact formation by engineering a coactivator (top) and after (bottom) exposure to excess cholesterol
peptide or a coactivator mimic (e.g., the PreScission sulfate. The presence of a single adduct indicates a 1:1
cleavage site) at the N terminus of a NR LBD could be stoichiometry, as expected from the X-ray structure, and
a general approach to generate better diffracting crystal shows the specific binding of both compounds. ESI-MS
forms. of the cholesterol sulfate complex yielded a major peak
of 31,983 Da (MW of apo ROR LBD is 31,516 Da),
which means that the adduct has a MW of 467 Da.Cholesterol Is Bound to ROR: Confirmation
This corresponds to the MW of the free acid form ofby Mass Spectrometry
cholesterol sulfate. Less than 2% of the cholesterolWe have used mass spectrometry to confirm the pres-
complex was remaining after exposure to excess cho-ence of cholesterol in the ROR LBD. The use of elec-
lesterol sulfate.trospray ionization mass spectrometry (ESI-MS) for the
identification and study of protein-ligand complexes, in
particular applied to nuclear receptors such as PPAR, Mutations that Prevent Binding of Cholesterol
Impair ROR Transcriptional ActivityRAR, RXR, and ERR3, has already been reported [24,
34, 35]. ESI-MS, using solvent and ionization conditions Several X-ray studies of LBDs overexpressed in E. coli
have reported the presence of fortuitous lipidic ligandsoptimized for detection of noncovalent complexes, was
therefore performed on ROR LBD produced in Sf-9 bound to the LBP [25, 36–38]. In the case of ROR [25],
stearic acid turned out to be a pseudoligand necessaryinsect cells. Two major molecular weights were calcu-
lated, namely 31,516 Da and 31,902 Da, which corre- to stabilize the LBD, but without biological activity.
Therefore, we tested whether cholesterol is a pseudoli-sponded to the N-tagged ROR LBD and to the same
protein carrying an adduct of 386 Da (Figure 3). This gand or a physiological ligand of ROR. Based on the
X-ray structure of ROR, a series of point mutations inadduct disappeared when collision-induced dissocia-
tion in the atmosphere-vacuum interface was provoked, the LBP was designed which should reduce binding of
cholesterol by steric hindrance. In addition, the mutationindicating a noncovalent binding between the protein
and this adduct. Cholesterol is a compound with a mo- Y507F was proposed which should prevent or reduce
the stabilization of H12 in the agonist position via losslecular weight of 386 Da. Further analysis by GC-MS of
a hexane extract of ROR LBD confirmed the presence of the hydrogen bond between Y507 and H484. These
Crystal Structure and Ligand of ROR
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Figure 5. ROR Transcriptional Activity Is Inhibited by Lovastatin
Treatment
Cells were transiently transfected as described in Experimental Pro-
cedures. After transfection, cells were treated with increasing doses
of lovastatin (1–25 	M) in a medium containing 10% FCS without
LDL. Forty-eight hours after transfection, cells were collected with
250 	l passive lysis buffer, and luciferase activity was determined
in duplicate on 20	l cell extracts from three separate culture dishes.
Luminescence data were corrected with -galactosidase (-Gal)
activity and expressed as relative luminescence unit (RLU)/-gal
unit. The figure shows the mean  SEM and is representative of
three independent experiments.
mutations have been performed by site-directed muta-
genesis on full-length ROR and were compared in a
transient transfection experiment to their wild-type
counterpart for their ability to activate the ROREtkluc
Figure 6. Cholesterol Partially Restores ROR Transcriptional Ac-
reporter gene. As shown in Figure 4A, all mutations, tivity in Cholesterol-Depleted Cells
except F399W, significantly reduced the transcriptional (A) Cells were transfected as described in Experimental Procedures.
activity of RORon a ROREtkluc reporter gene, although After transfection, cells were treated with HPCD (10 mM) in the
to different extents. The side chain of the mutated W399 presence or absence of 5 	M lovastatin for 4 hr in a medium con-
taining 10% LDL-free serum. After 4 hr, the medium was removedhas the possibility of adopting a conformation for which
and cells were treated with a medium containing 10% LDL-freeno steric clash with cholesterol in the LBP occurs, pro-
serum.vided that the side chains of R483 and K487 (both at
(B) Cells were treated with HPCD (10 mM) in the presence of 5 	M
the surface) concomitantly change their conformations. lovastatin for 4 hr in a medium containing 10% LDL-free serum.
This provides an explanation for the only slight loss of After 4 hr, the medium was removed and the cells were treated with
transcriptional activity for the F399W mutation. For the vehicle (ethanol or DMSO) or cholesterol or cholesterol derivatives
as indicated at 10 	M in the presence of 5 	M lovastatin. Twenty-other mutations in the LBP there are no alternate low-
four hours after transfection, cells were collected with 250	l passiveenergy side chain conformations possible that would
lysis buffer and luciferase activity was determined in duplicate onprevent a steric clash with cholesterol. This explains
20	l cell extracts from three separate culture dishes. Luminescence
why they all show strongly reduced transcriptional activ- data were corrected with -galactosidase (-Gal) activity and ex-
ities. In particular, the activity for mutants A371Q and pressed as relative luminescence unit (RLU)/-gal unit. Data are
H484W correspond to the activity elicited by an empty expressed as fold induction  SEM and are representative of three
independent experiments.vector. The mutation Y507F leads to a 40% loss in tran-
scriptional activity, showing that the hydrogen bond be-
tween Y507 and H484 contributes to the stabilization of
parent constitutive activity of ROR could thus be ex-H12 in the agonist position. Western blot analysis of cell
plained by the ubiquitous presence of an endogenousextracts obtained from cells transfected with wild-type
ligand (cholesterol or a cholesterol derivative).and ROR mutant constructs showed that their expres-
sion levels were similar (Figure 4B), with the exception
of A371Q, which was found to be more expressed when ROR Transcriptional Activity Is Modulated
by Lovastatin, an Inhibitor ofcompared to other mutants or wild-type. Nevertheless,
this mutant displays a very low transcriptional activity. It the HMG-CoA Reductase
The level of intracellular cholesterol in mammalian cellsis possible that some mutants, even though expressed,
might not be properly folded. Taken together, these data is determined by the uptake of circulating LDL-choles-
terol that is present in serum, and by cholesterol pro-indicate that the active form of ROR is indeed bound
to cholesterol or to a cholesterol derivative, which stabi- duced by endogenous synthesis from acetyl-CoA
through the mevalonate pathway [39]. The intracellularlizes the receptor in an agonistic conformation. The ap-
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cholesterol level is controlled through feedback regula- Since H12 in this X-ray structure is in the agonist posi-
tion, it was predicted that cholesterol should activatetion, which involves the LDL receptors, HMG-CoA re-
ductase, and the sterol regulatory element binding pro- ROR. This was further supported by the finding that a
mimic of a coactivator peptide, namely the PreScissiontein (SREBP) [40]. We used the lipid-lowering drug
lovastatin [41] to specifically inhibit the HMG-CoA re- site, was bound to AF-2, making the classic coactivator
interactions [22]. The ubiquitous presence of cholesterolductase activity, the rate-limiting step in cholesterol syn-
thesis. As shown in Figure 5, treatment with lovastatin in vivo could thus explain the apparent constitutive ac-
tivity of ROR. We further present data that support thedecreased the ROR transcriptional activity in a dose-
dependent manner, further supporting the hypothesis view that cholesterol is not a pseudoligand, since we
have found that ROR transcriptional activity was in-that the in vivo transcriptional activity of ROR is modu-
lated by a ligand that belongs to the cholesterol deed modulated by changes in intracellular cholesterol
level. We cannot, however, at this stage exclude thepathway.
possibility that these effects are indirect, via an influence
of cholesterol on lipid raft function, which thus couldCholesterol Can Positively Regulate ROR
modulate signal transduction in the cell. We have shownTranscriptional Activity
by MS that cholesterol bound to the LBP of ROR canWe next wanted to establish whether in eukaryotic cells
be exchanged with cholesterol sulfate. This shows thatpartially depleted of cholesterol, ROR transcriptional
cholesterol is not an unexchangeable structural cofactoractivity could be reconstituted by addition of choles-
like, for example, the fatty acids bound to HNF4 [43].terol. We therefore treated the cells with hydroxypropyl-
Our results cannot completely rule out the possibility
-cyclodextrin (HPCD), a cyclodextrin derivative known
that cholesterol or a cholesterol derivative acts as anto function as a cholesterol shuttle [42]. HPCD treatment
“exchangeable structural cofactor” needed for properis used in experiments aiming at the partial depletion of
folding, and that the activity of RORmight be regulatedintracellular cholesterol. In order to prevent an increase
in addition in a different way (e.g., by posttranslationalof intracellular cholesterol through the activation of the
modification). We nevertheless propose the hypothesismevalonate pathway, cells were also treated with lova-
that ROR bound to cholesterol or to a cholesterol deriv-statin while they were fed with a medium containing
ative acts as a lipid sensor of the intracellular cholesterolLDL-free serum. As shown in Figure 6A and in agreement
level. ROR could thus modulate a panel of genes, yetwith data obtained with lovastatin, treatment of the cells
to be identified, as a counterpart to LXR and FXR. Thewith HPCD, in the absence or presence of lovastatin,
latter orphan NRs have been found to play an importantdramatically decreased the transcriptional activity of
role in the control of cholesterol homeostasis [27].ROR. Using a combination of HPCD and lovastatin, we
The broad and ubiquitous role of cholesterol is remi-found (Figure 6B) that transcription of the RORE reporter
niscent of the multiple syndromes described in the caseis stimulated in response to cholesterol, epicholesterol,
of defects of the cholesterol pathway [44] and is consis-and cholestanol, and to an even greater extent by cho-
tent with the various phenotypes described in the RORlesterol sulfate and 7-dehydrocholesterol. In contrast,
mutant mice [18]. Among these, a severe atherosclerosisall the hydroxycholesterols tested did not display signifi-
and hypolipoproteinemia have been observed in stag-cant activity and the cholesterol derivative 5-cholesten-
gerer mice [16]. Hypercholesterolemia is primarily linked24-ethyl-3-ol-acetate also did not trigger any increase
to development of atherosclerosis, and ROR has alsoin ROR transcriptional activity when compared with
been shown to regulate apolipoproteins A and C [8,vehicle. These data correlate well with docking studies
9]. In addition, ROR has been implicated in vascularon cholesterol derivatives using our X-ray structure of
inflammation for which multiple links have been estab-ROR.
lished with atherosclerosis [45]. In several of these dis-For cells not treated with HPCD or lovastatin, we did
ease states in which cholesterol plays an important rolenot detect stimulation of transcriptional activity upon
ROR could thus constitute the missing molecular linkaddition of cholesterol. This can be explained by the
and be an important novel drug target.abundant presence of endogeneous cholesterol.
Experimental Procedures
Discussion and Biological Implications
Cloning, Protein Expression, and Purification
A transfer vector carrying the human ROR1 LBD (residues 271–523)This report describes the first X-ray structure of the LBD
flanked by an N-terminal hexa-His tag and a PreScission cleavageof the orphan nuclear receptor ROR, at 1.63 A˚. The
site was cotransfected with linearized BacPAK8 (Clontech) virusX-ray structure unexpectedly revealed that a ligand
DNA into Sf-21 insect cells using lipofection. Virus stocks were(which had been taken up during fermentation in Sf-9
generated by amplification in Sf-9 cells and large-scale expression
cells) was present in the LBP. This is in contrast with the was performed in Wave Bioreactors using predetermined optimal
previous opinion that ROR is a constitutive activator of conditions of 1 MOI at 1.82  106 cells/ml (TOI) for 72 hr. Frozen
cell pellets were homogenized in 50 mM Tris-HCl (pH 8.0), 500 mMtranscription in the absence of exogenous ligands [23].
NaCl, 10 mM -mercaptoethanol, 0.6 mM PMSF, and the proteaseThe ligand was identified with the high-resolution elec-
inhibitor cocktail Complete/EDTA free (Roche Molecular Biochemi-tron density map to be cholesterol. This finding was
cals), and sonicated and centrifuged before affinity chromatographyconfirmed by mass spectrometry analysis. The good fit
on Ni-NTA Superflow resin (Qiagen). The protein was eluted with a
of cholesterol to the hydrophobic part of the LBP led to gradient of 20–500 mM imidazole and was further purified by anion
the hypothesis that cholesterol or a cholesterol deriva- exchange chromatography (Qsepharose-HP 16/10) and size exclu-
sion chromatography (Superdex SPX75/16/60; Amersham Biosci-tive might be the natural, physiological ligand of ROR.
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ences). The ROR LBD in 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, model (using the second, higher resolution native data set; Table
1, native 2) with Rcryst  19.9% and Rfree  23.0% (no sigma cutoff,5 mM DTT was concentrated to 14 mg/ml prior to crystallization.
The resulting protein was estimated to be 95% pure and homoge- 15 A˚–1.63 A˚, working set of 26,570 unique reflections, test set of
1,907 reflections). In general, the electron density is of excellentneous by SDS-PAGE and reverse phase HPLC. Mass spectrometry
was performed on a Q-Tof (Micromass) quadrupole time-of-flight quality (Figure 2B), except for amino acids 461–464 (L9-10), which
had only weak density. The protein part of the refined model consistshybrid tandem mass spectrometer equipped with a Micromass
Z-type electrospray ionization source (ESI). The measured molecular of the last two His amino acids from the His tag, followed by the
PreScission site (LEVLFQG) and by amino acids 271–511 of themass of 31,515.4 Da of the protein corresponded to acetyl-
GSSHHHHHHLEVLFQGP-ROR-LBD271–523. In some initial experi- ROR LBD. The refined model also contains 419 water molecules
and one cholesterol molecule. Refinement was initially done withments, the N-terminal polyhistidine tag of ROR LBD was cleaved
after the affinity chromatography step by the PreScission protease X-PLOR with the first native data set. The final rounds of refinement
were done with the higher resolution data set and using REFMAC(Amersham Biosciences) according to the manufacturer’s instruc-
tions (2 U/100	g protein). SDS-PAGE and mass spectrometry analy- v5.0 (CCP4, 1994). The quality of the model was assessed with
PROCHECK v3.3 and REFMAC v5.0. 94.1% of the amino acids aresis of the cleaved protein showed a homogeneous protein that how-
ever failed to crystallize. in the most favored region and 5.9% are in the additionally allowed
region of the Ramachandran plot (no amino acids are in disallowed
regions). The overall G factor is 0.39, with rms bond lengths Crystallization and Data Collection
0.009 A˚ and rms bond angles  1.11. The volume of cholesterolThe ROR LBD crystals were grown at 20C by the hanging drop
and the probe-occupied volume of the LBP (considering water mole-method. No coactivator peptide or other ligands were added to the
cules in the LBP to be a part of the protein) were determined withprotein solution. The first native data set (1.88 A˚ resolution) and
VOIDOO [50] using a probe radius of 1.4 A˚.the Hg derivative data set (1.94 A˚ resolution) were collected using
crystals obtained with a reservoir of 100 mM Tris-HCl (pH 8.4), 19%
PEG 6000, 0.2 M CaCl2. They form in space group P21, contain one ESI-MS and Exchange Experiments
monomer in the asymmetric unit, and have unit cell dimensions of Mass spectrometry was carried out using a Q-Tof (Micromass) quad-
a  55.9 A˚, b  49.9 A˚, c  60.7 A˚,   98.7. For the Hg derivative, rupole time-of-flight hybrid tandem mass spectrometer equipped
a crystal was soaked prior to data collection for 1 hr in 5 	l of with a Micromass Z-type electrospray ionization source (ESI). The
solution containing 4 mM methylmercuric acetate in addition to the acquisition mass range was typically m/z 1500–4500 in 5 s. Calibra-
reservoir composition. The unit cell for the Hg derivative crystal after tion was achieved by using the multiple charged ion peaks from
soaking was a  55.6 A˚, b  50.0 A˚, c  60.1 A˚,   98.0. The hen egg lysozyme (MW 14,305.1 Da). The mass spectrometer was
following cysteine amino acids reacted with methylmercuric acetate: tuned in order to allow detection of multiple charged species at
C288, C396, C472, and C481. After structure solution by SIRAS and high mass-to-charge (m/z) ratio. Proteins were typically desalted at
subsequent refinement to 1.88 A˚, a second native data set (1.63 A˚ a final concentration of 15 	M in 50 mM ammonium acetate buffer
resolution) could be collected from an isomorphous crystal (a  (pH 7.0). Cholesterol sulfate (MW 466.7, CholSO4H) was dissolved
54.8 A˚, b  49.7 A˚, c  60.5 A˚,   98.4) obtained with a reservoir at 50 mM in DMSO and added at 2.5 mM final concentration to the
of 100 mM Na HEPES (pH 7.5), 100 mM Na-Ac, 22% PEG 4000. This (His)6ROR-LBD270–523 solution (135 	M). The resulting solution was
second native data set was used for the final refinement steps. For incubated overnight at 37C. A control experiment was done by
the native and derivative data collections at 105K, crystals were incubating the same amount of ROR LBD protein with 5% DMSO
flash-frozen in crystallization buffer supplemented with 20% glyc- under identical conditions.
erol. All diffraction data were collected at the Swiss-Norwegian
beamline (SNBL) of the European Synchrotron Radiation Facility
Reagents and Plasmids(ESRF) using a wavelength of   0.8727 A˚. Data were processed
The human osteosarcoma cell line, U-2OS (ATCC; Crl HTB 96), waswith DENZO and SCALEPACK [46].
purchased from ATCC. Cholesterol, 5-cholesten-3-ol (epicholest-
erol), 5-cholestan-3ol (cholestanol), 7-dehydrocholesterol, 22(R)Structure Determination and Refinement
hydroxycholesterol, 20(S) hydroxycholesterol, cholesterol sulfate,Attempts to solve the structure by molecular replacement were not
and 5-cholesten-24-ethyl-3-ol-acetate were purchased fromsuccessful. Data from a single-wavelength experiment on the mer-
Steraloids. 27-hydroxycholesterol was purchased from Researchcury-substituted crystal were thus used together with a native data
Plus. Hydroxypropyl--cyclodextrin (HPCD) was obtained fromset (Table 1, native 1) for the initial phasing by SIRAS to 1.94 A˚.
Cyclodextrin Technologies Development. LDL-free serum and lo-Anomalous and isomorphous difference Patterson maps revealed
vastatin were obtained from Sigma-Aldrich. The pCMX-ROR plas-at least one common dominant peak. SnB version 2.1 [47] with
mid was a kind gift from Dr. M. Becker-Andre (Serono). The reporterDREAR normalization [48] using the observed anomalous differ-
ROREtkluc was a kind gift from Dr. V. Giguere (McGill University)ences was used to determine four Hg sites. The heavy atom parame-
and has been previously described [6].ters were refined using MLPHARE version 4.1 [49] which yielded a
mean figure of merit of 0.31 and an overall phasing power of 1.16
for the acentric data in the resolution range 10 A˚–1.94 A˚. Subsequent Cell Culture and Transfection Assays
density modification with DM [49] resulted in an excellent SIRAS- Cells were seeded in 12-well plates at a density of 1  105 cells/
map. Skeletonization with MAPMAN enabled chain tracing and cm2, 24 hr before transfection, and transfected using Fugene6 trans-
model building with O version 7.0 [31]. fection reagent. A typical reaction mixture contained 0.5 	g pCMX-
After building the major part of the protein (amino acids A271– ROR expression vector, 1.0 	g reporter plasmid ROREtkluc, 0.1
F511) and insertion of 112 water molecules into the experimental
	g pCMV--Gal, and 3 	l Fugene6. After a 4 hr exposure to the
SIRAS map, several alternate cycles of refinement and manual re- transfection mix, the medium was refreshed and left for another 24
building resulted in a model with Rcryst  28.1% (8 A˚–1.88 A˚), which hr. Transfected cells were subsequently harvested for the luciferase
gave excellent 2Fo  Fc and Fo  Fc maps (Figure 2A) for a ligand assay by scraping the cells into 250 	l passive lysis buffer after
unexpectedly present in the LBP. A small molecule X-ray structure washing them in phosphate-buffered saline. Luciferase activity was
of 26-hydroxycholesterol from the Cambridge Structural Database monitored according to the Promega luciferase assay kit using an
(entry FIZDUN) showed a perfect, unambiguous fit (after removal of automatic luminometer LB96P (Berthold). Results are expressed in
the 26-hydroxy group and rotation of 120 around the C24-C25 bond) relative light units (RLU) per -galactosidase (-Gal) unit.
into this unbiased electron density. The excellent quality of the high-
resolution map thus allowed the identification of the ligand as being
cholest-5-en-3-ol (cholesterol). This finding was later confirmed Wild-Type and Mutant Expression Vector
The ROR mutants C323L, A330L, A371Q, F399W, and Y507F wereby GC-MS (F.B. et al., unpublished data). The ligand cholesterol
was built into the electron density and further cycles of refinement, generated using a Quick-change XL site-directed mutagenesis kit
from Stratagene.model rebuilding, and insertion of water molecules yielded the final
Structure
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